Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus

  • Sabina Semiz Department for Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo
  • Tanja Dujic Department for Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo
  • Barbara Ostanek Department for Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana
  • Besim Prnjavorac General Hospital Tesanj, Brace Pobrica
  • Tamer Bego Department for Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo
  • Maja Malenica Department for Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo
  • Janja Marc Department for Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana
  • Adlija Causevic Department for Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo
Keywords: drug-metabolising enzymes, CYP2C9, CYP2C19, CYP2D6, diabetes, pharmacogenetics

Abstract

This is the first study performed in population from Bosnia & Herzegovina (BH), in which we analysed a significance of genetic variations in drug-metabolising enzyme, cytochrome P450 (CYP), in pathogenesis of Type 2 diabetes. We have determined allele frequencies for CYP2C9*2, CYP2C19*2, and CYP2D6*4 in diabetic patients and nondiabetic controls. Genomic DNA was extracted from blood samples collected from 37 diabetic and 44 nondiabetic subjects. A real-time polymerase chain reaction was used for the detection of specific CYP polymorphisms, with the application of the specific TaqMan’ SNP genotyping tests (AppliedBiosystems). Interestingly, results from this study have demonstrated that frequencies of CYP2C19*2 and CYP2D6*4 variants were in line, while frequency of CYP2C9*2 polymorphism seemed to be lower in this sample of BH population as compared to the Caucasians genotype data. Furthermore, no significant difference in allele frequencies for CYP2C9*2, CYP2C19*2, and CYP2D6*4 was demonstrated between diabetic and nondiabetic subjects. Thus, results form this study seem to indicate no relationship between CYP2C9, CYP2C19, and CYP2D6 genotype and diabetes susceptibility in Bosnian population. This in part may reflect a limited study population included in our study and would require larger cohorts to reveal potential relationships between analysed CYP genetic variants and diabetes risk. In addition, it would be pertinent to further explore possible effects of CYP genetic variations on therapeutic and adverse outcomes of oral antidiabetics, which might be the key in optimising therapy for individual patient with Type 2 diabetes.

Downloads

Download data is not yet available.
Published
2010-11-20
How to Cite
1.
Semiz S, Dujic T, Ostanek B, Prnjavorac B, Bego T, Malenica M, Marc J, Causevic A. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. BJBMS [Internet]. 20Nov.2010 [cited 22Mar.2019];10(4):287-91. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/2662
Section
Molecular Biology